Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Recommendation of “Hold” by Brokerages

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been given an average recommendation of “Hold” by the six analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $27.8333.

A number of brokerages recently issued reports on KMTS. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. The Goldman Sachs Group decreased their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. BTIG Research upped their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th.

Kestra Medical Technologies Trading Down 2.4%

NASDAQ:KMTS opened at $21.06 on Friday. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies has a 1-year low of $14.10 and a 1-year high of $30.00. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -8.70 and a beta of 0.47. The business’s 50-day moving average price is $22.33 and its two-hundred day moving average price is $22.56.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. On average, equities analysts expect that Kestra Medical Technologies will post -2.29 earnings per share for the current year.

Insider Activity at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the sale, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Kestra Medical Technologies

A number of large investors have recently bought and sold shares of the business. Farther Finance Advisors LLC acquired a new stake in Kestra Medical Technologies during the 4th quarter worth approximately $31,000. Russell Investments Group Ltd. boosted its holdings in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares during the period. BNP Paribas Financial Markets increased its position in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after acquiring an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in Kestra Medical Technologies in the 4th quarter valued at $72,000. Finally, Brown Brothers Harriman & Co. lifted its position in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.